Bilcare India Stand Alone Reached Revenue of Rs 93.70 Cr.; Up By 28 Percent

Published: Jul 30, 2007

PUNE, India, July 30 /PRNewswire/ -- Bilcare Ltd., service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market, posted their results for the first quarter ended June 30, 2007.

The India stand alone Revenue of the Company for the first quarter ended June 30, 2007 stood at Rs 93.70 Cr. as against Rs 73.19 Cr. in the corresponding quarter of the previous year, showing a growth of 28 percent. This resulted in an EBIDTA of Rs 26.83 Cr as against Rs 20.42 Cr. in the corresponding quarter of the previous year, registering a growth of 31 percent.

"Bilcare has already started reaping the rewards of our investments in creating a global infrastructure to meet the key challenges of big pharma worldwide," said, Mohan Bhandari, Chairman Bilcare Ltd.

The Consolidated Revenue for the quarter ended-Q1 FY08, stood at Rs 131.86 Cr. This resulted in a better consolidated earnings before interest depreciation, tax and amortization (EBIDTA) of Rs 32.04 Cr. and a Net Profit of Rs 16.53 Cr.

The Research Service business has expanded its reach globally with service centers being established at multiple sites. This has resulted in signing agreement with some of the major global pharma companies for their Research Service requirements. Bilcare filed three patents on packaging innovations addressing product identity and other multiple consumer concerns like counterfeit and compliance.

Bilcare Research Academy in association with ACRP, US, launched its first center to offer one year Post Graduate Program in "Clinical Research Management." The first batch has already started in its Pune center.

About Bilcare:

Headquartered in Pune, Bilcare provides integrated packaging solutions across the entire spectrum of pharmaceutical value chain through five focused business activities -- Research Services, Clinical Services, Design Lab, Research Academy and Packaging Materials. Bilcare operates state-of-the art manufacturing facilities in India, Singapore, US and UK and has regional offices in Brazil, Germany, China & Australia which caters to global clients (J&J, Merck, GSK, Sanofi, Pfizer, Novartis, Wyeth, Ranbaxy, Dr. Reddy to name a few). Bilcare Research is increasingly changing the face of pharma industry by enabling global pharmaceuticals companies and their brands with better communication, patient compliance, cost, convenience and checking counterfeit through its innovative solutions.

Bilcare Ltd.

CONTACT: Vincent Lagrotteria, Vice President, Global Sales and Marketingof Bilcare Ltd., +1-610-422-3178, Fax: +1-610-935-4321,

Back to news